VYNE Therapeutics (formerly Menlo Therapeutics) to Present at the Cantor Fitzgerald and H.C. Wainwright Investment Conferences in September
VYNE Therapeutics Inc. announced that David Domzalski, Chief Executive Officer, will present at the upcoming H.C. Wainwright 22nd Annual Global Investment Conference and the Cantor Fitzgerald Virtual Global Healthcare Conference. H.C. Wainwright Annual Global Investment Conference Date: September 14 Time: 2:30pm Eastern Time Webcast: https://wsw.com/webcast/hcw7/vyne/1630674 Cantor Fitzgerald Virtual Global Healthcare Conference Date: September 16 … Continue reading VYNE Therapeutics (formerly Menlo Therapeutics) to Present at the Cantor Fitzgerald and H.C. Wainwright Investment Conferences in September Continue Reading
Healthpeak Properties, Inc. announced today that its CEO, Tom Herzog, will present at the BofA Securities 2020 Global Real Estate Virtual Conference. About Healthpeak Properties Healthpeak Properties, Inc. is a fully integrated real estate investment trust (REIT) and S&P 500 company. Healthpeak owns and develops high-quality real estate in the three private-pay healthcare asset classes of … 
Kaskela Law LLC announces that it is investigating Patterson Companies, Inc. on behalf of the Company’s stockholders. A securities fraud complaint was filed against Patterson in federal court on behalf of investors who purchased shares of the Company’s stock between June 26, 2013 and February 28, 2018. According to the complaint, during that time period Patterson engaged in a “coordinated … 
Kaskela Law LLC announces that it is investigating Akcea Therapeutics, Inc.on behalf of the company’s shareholders. On August 31, 2020, Akcea announced that it had entered into an agreement to be acquired by Ionis Pharmaceuticals, Inc. (“Ionis”) for $18.15 per share in cash. The firm’s investigation seeks to determine whether Akcea’s directors breached their fiduciary duties in agreeing … 
Pfizer Inc. and BioNTech SE announced preliminary preclinical data in mouse and non-human primate models from their BNT162b2 mRNA-based vaccine program against SARS-CoV-2, the virus that causes COVID-19 disease. In a non-human primate preclinical study, immunization with BNT162b2, a nucleoside-modified messenger RNA (modRNA) candidate, protected rhesus macaques against SARS-CoV-2 infection. The manuscript describing these preclinical data is … 
Kaskela Law LLC announces that it is investigating Aimmune Therapeutics, Inc. on behalf of the company’s shareholders. On August 31, 2020, Aimmune announced that it had entered into an agreement to be acquired by Sociétés des Produits Nestlé, S.A. (“Nestle”) for $34.50 per share in an all-cash transaction. The firm’s investigation seeks to determine whether Aimmune’s directors breached their …